ASCO GU 2018 Prostate Cancer
Viewing 21-40 of 88 articles
ASCO GU 2018: Proportion of Biochemically-recurrent Prostate Cancer Patients with Durable Undetectable PSA After Short-course Androgen Deprivation Therapy
ASCO GU 2018: First Interim Analysis Of REASSURE, An Observational Study To Assess The Safety Of Radium-223 In Men With Metastatic Castration-resistant Prostate Cancer
ASCO GU 2018: Abiraterone Acetate in Patients Aged 75 or More with mCRPC in Both Pre-chemotherapy or Post-chemotherapy Settings
ASCO GU 2018: Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
ASCO GU 2018: Adjuvant Enzalutamide (ENZA) for Men with Non-metastatic High-risk Prostate Cancer (HRPCa) After Radical Prostatectomy (RP).
ASCO GU 2018: Daily Versus Weekly Prostate Cancer image-guided Radiotherapy: A Phase 3, Multi-center, Randomized Trial
ASCO GU 2018: Comparison of Enzalutamide and Bicalutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer - STRIVE Study
ASCO GU 2018: Treatment Duration And Utilization Patterns In Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide or Abiraterone Acetate
ASCO GU 2018: Debate: Is there Evidence for Local treatment in Patients with Newly Diagnosed Metastatic Disease?
ASCO GU 2018: Impact Of Statins On Outcomes In Patients With mCRPC: COU-AA-301 and COU-AA-302 Trials
ASCO GU 2018: Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes